Page 7 - Pascal Deschatelets News Today

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) Director Alec Machiels sold 1,250 shares of the business’s stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $88.66, for a total transaction of $110,825.00. Following the transaction, the director now owns 267,641 shares of the company’s stock, valued at […]

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) had its target price hoisted by Oppenheimer from $96.00 to $108.00 in a research note issued to investors on Friday morning, The Fly reports. APLS has been the topic of a number of other reports. Robert W. Baird raised their price target on shares of Apellis Pharmaceuticals from $90.00 […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) shares gapped down before the market opened on Tuesday . The stock had previously closed at $88.11, but opened at $82.50. Apellis Pharmaceuticals shares last traded at $84.71, with a volume of 597,729 shares. Analyst Upgrades and Downgrades Several equities research analysts recently weighed in on APLS shares. […]

Skandinaviska Enskilda Banken AB publ decreased its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 16.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 30,846 shares of the company’s stock after selling 6,208 shares during the period. Skandinaviska Enskilda Banken […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) insider Pascal Deschatelets sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, May 8th. The shares were sold at an average price of $92.39, for a total value of $1,108,680.00. Following the completion of the transaction, the insider now directly owns 1,033,813 shares […]

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) had its target price boosted by Citigroup from $88.00 to $106.00 in a report published on Monday morning, The Fly reports. Several other research firms have also commented on APLS. HC Wainwright increased their price target on shares of Apellis Pharmaceuticals from $87.00 to $100.00 in a research report […]

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) had its price target raised by Bank of America from $112.00 to $114.00 in a report published on Friday, The Fly reports. APLS has been the topic of several other research reports. HC Wainwright boosted their price objective on Apellis Pharmaceuticals from $87.00 to $100.00 in a report on […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) has earned an average recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) has been assigned an average recommendation of “Moderate Buy” from the fourteen brokerages that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the […]

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) issued its quarterly earnings data on Thursday. The company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.42) by ($0.14), Briefing.com reports. The business had revenue of $44.80 million during the quarter, compared to the consensus estimate of $26.10 million. Apellis Pharmaceuticals had a […]